1. Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis
- Author
-
Roberta Rigolio, Benedetta Mazzanti, L Stanzani, Francesco Lolli, L Crippa, E Di Luccio, Norberto Oggioni, Guido Cavaletti, E. Tagliabue, Tiziana Biagioli, F Sala, Ennio Cavalletti, Chiara Zoia, V Sala, S Galbiati, Paolo Perseghin, Giovanni Tredici, Paolo Riccio, Stefania Rota, Maria Dassi, Maura Frigo, Cavaletti, G, Cavalletti, E, Crippa, L, Di Luccio, E, Oggioni, N, Mazzanti, B, Biagioli, T, Sala, F, Sala, V, Frigo, M, Rota, S, Tagliabue, E, Stanzani, L, Galbiati, S, Rigolio, R, Zoia, C, Tredici, G, Perseghin, P, Dassi, M, Riccio, P, and Lolli, F
- Subjects
Encephalomyelitis, Autoimmune, Experimental ,T-Lymphocytes ,CD3 ,Encephalomyelitis ,Immunology ,chemistry.chemical_compound ,Immunosuppressive Agent ,Animals ,Humans ,Immunology and Allergy ,Medicine ,Lymphocyte Count ,Cells, Cultured ,Mitoxantrone ,Cardiotoxicity ,Isoquinoline ,Pixantrone ,biology ,business.industry ,Animal ,Multiple sclerosis ,Isoquinolines ,medicine.disease ,In vitro ,Rats ,Neurology ,chemistry ,T-Lymphocyte ,Acute Disease ,Chronic Disease ,biology.protein ,Rat ,Female ,Neurology (clinical) ,business ,Immunosuppressive Agents ,CD8 ,Cell Division ,medicine.drug ,Human - Abstract
Pixantrone is less cardiotoxic and is similarly effective to mitoxantrone (MTX) as an antineoplastic drug. In our study, pixantrone reduced the severity of acute and decreased the relapse rate of chronic relapsing experimental allergic encephalomyelitis (EAE) in rats. A marked and long-lasting decrease in CD3+, CD4+, CD8+ and CD45RA+ blood cells and reduced anti-MBP titers were observed with both pixantrone and MTX. In vitro mitogen- and antigen-induced T-cell proliferation tests of human and rodents cells evidenced that pixantrone was effective at concentrations which can be effectively obtained after i.v. administration in humans. Cardiotoxicity was present only in MTX-treated rats. The effectiveness and the favorable safety profile makes pixantrone a most promising immunosuppressant agent for clinical use in multiple sclerosis (MS).
- Published
- 2004